A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines ...
Schizophrenia affects how a person thinks, feels and behaves, and can cause paranoia, delusions, hallucinations, and changes in emotions, movements and behavior. Those symptoms can disrupt a patient's ...
The Food and Drug Administration (FDA) approved Bristol Myers Squibb’s schizophrenia drug Cobenfy Thursday — the first new approved drug for the disease in some 30 years. The drug, a combination of ...
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel treatment for schizophrenia in decades. Reading time 3 minutes People living with ...
A novel drug, evenamide, quieted overactive brain circuits in an animal model of schizophrenia, improving memory, social interaction, and dopamine balance, offering hope for tackling symptoms that ...
Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...
The Food and Drug Administration on Thursday approved Bristol Myers Squibb's highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results